Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy
10.1016/j.jhep.2014.08.021
Saved in:
Main Authors: | Marcellin Patrick, Wursthorn Karsten, Wedemeyer Heiner, Chuang Wan Long, Lau George, Avila Claudio, Peng Cheng Yuan, Gane Edward, Lim Seng Gee, Fainboim Hugo, Foster Graham R., Safadi Rifaat, Rizzetto Mario, Manns Michael, Bao Webin, Trylesinski Aldo, Naoumov Nikolai |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
Elsevier
2016
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/127459 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
by: Y. Wang, et al.
Published: (2018) -
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
by: Wang Y., et al.
Published: (2014) -
Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
by: Y. Wang, et al.
Published: (2018) -
Telbivudine versus lamivudine in patients with chronic hepatitis B
by: Ching Lung Lai, et al.
Published: (2018) -
Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: Results from the 2-year roadmap strategy
by: Teerha Piratvisuth, et al.
Published: (2018)